Table 4.
No. of Isolates AST Reference a |
No. of Isolates MICPNEG1 b | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Antimicrobial | Total | R | I | S | R | I | S | CA c (no. [%]) |
mE d (no. [%]) |
ME e (no. [%]) |
VME f (no. [%]) |
Ampicillin | 112 | 100 | 0 | 12 | 99 | 0 | 13 | 111 (99) | 0 (0) | 0 (0) | 1 (1) |
Amoxicillin/Clavulanic Acid | 112 | 72 | 0 | 40 | 73 | 0 | 39 | 109 (97) | 0 (0) | 2 (2) | 1 (1) |
Ceftazidime | 112 | 47 | 2 | 63 | 49 | 0 | 64 | 108 (96) | 3 (3) | 1 (1) | 0 (0) |
Ceftriaxone | 112 | 50 | 0 | 62 | 51 | 1 | 60 | 110 (98) | 1 (1) | 1 (1) | 0 (0) |
Piperacillin/Tazobactam | 112 | 39 | 4 | 69 | 39 | 4 | 69 | 106 (93) | 6 (7) | 0 (0) | 0 (0) |
Ciprofloxacin | 112 | 51 | 4 | 57 | 53 | 4 | 55 | 106 (93) | 4 (4) | 2 (2) | 0 (0) |
Amikacin | 112 | 16 | 4 | 92 | 14 | 5 | 93 | 106 (93) | 5 (6) | 0 (0) | 1 (1) |
Gentamicin | 112 | 40 | 5 | 67 | 40 | 4 | 68 | 104 (92) | 4 (4) | 2 (2) | 2 (2) |
Trimethoprim/Sulfamethoxazole | 112 | 69 | 1 | 42 | 69 | 0 | 43 | 108 (96) | 1 (1) | 1 (1) | 2 (2) |
Chloramphenicol | 112 | 47 | 0 | 65 | 47 | 0 | 65 | 112 (100) | 0 (0) | 0 (0) | 0 (0) |
Colistin | 112 | 12 | 0 | 77 | 12 | 0 | 77 | 110 (98) | 0 (0) | 1 (1) | 1 (1) |
Fosfomycin | 112 | 1 | 0 | 111 | 1 | 0 | 111 | 112 (100) | 0 (0) | 0 (0) | 0 (0) |
Tigecycline | 112 | 0 | 0 | 112 | 0 | 0 | 112 | 112 (100) | 0 (0) | 0 (0) | 0 (0) |
Meropenem | 112 | 16 | 6 | 90 | 17 | 6 | 79 | 106 (93) | 5 (6) | 1 (1) | 0 (0) |
Imipenem | 112 | 19 | 7 | 86 | 19 | 7 | 86 | 112 (100) | 0 (0) | 0 (0) | 0 (0) |
Ertapenem | 112 | 33 | 0 | 79 | 32 | 0 | 80 | 111 (99) | 0 (0) | 0 (0) | 1 (1) |
a Number of isolates tested with the reference method and classified as R resistant; I, susceptible, increased exposure; S, susceptible; b number of isolates tested with the evaluated method and classified as R resistant; I, susceptible, increased exposure; S, susceptible; c CA, categorical agreement; d mE, minor error; e ME, major error; f VME, very major error.